INTRODUCTION 4
Generating an effective and durable CTL response by vaccination in humans has been largely 6 9 attributable to live-attenuated vaccines (e.g., vaccinia, yellow fever) and non-replicating viral vectors 7 0 (rAD/MVA) [20] [21] [22] [23] . Despite the wealth of immune monitoring data that has been generated in recent 7 1 years, a knowledge gap still exists in our understanding of what determines the magnitude, diversity, and 7 2 persistence of vaccine-elicited CTL responses in humans. Early studies using "systems biology" 7 3 approaches have focused upon innate immune signatures that correlate with adaptive CD8 + T cell 7 4
responses. Querec et al. found that the induction of expression of the GCN2 kinase by the yellow fever 7 5 virus (YFV) 17D vaccine at early time points correlated with the frequency of acutely activated 7 6 (CD38 + HLA-DR + ) CD8 + T cells at day 15 post-vaccination [24] . However, they did not evaluate the 7 7 magnitude or function of the memory YFV-specific T cell response induced by the vaccine, nor the 7 8 associations of their findings with vaccine efficacy. In contrast, similar analysis of the Ad5-vectored 7 9
HIV vaccine studied in the STEP trial revealed a more rapid up-regulation of innate immune responses 8 0 than the YFV 17D vaccine, and cytokine responses, especially levels of MCP-2 and MCP-1, correlated 8 1 with the magnitude of the HIV-specific CD8 + T cell response measured by cytokine flow cytometry 8 2 [25] . More recent studies have focused on studying the relationship between acutely activated CD4 + and 8 3 CD8 + T cells after vaccination and during the subsequent convalescent phase. For example, a distinct 8 4 transcriptional and molecular signature in CD4 + T cells was used to distinguish effector phase versus 8 5 memory responses in BCG vaccinated individuals [26] . Greenough et al. demonstrated that particular 8 6 transcription factors (eomesodermin and T-bet) allowed the identification of CD8 + T cells that expanded 8 7 rapidly during acute infectious mononucleosis and enabled the proliferation and transition of these cells 8 8
to later differentiation stages in convalescence [27] . While these studies have revealed distinct 8 9 transcriptional signatures that correlate early immune activation of antigen-specific T cells with the 9 0 presence of long-term T cell responses, each has relied upon studying sorted T cells at the population 9 1 1 0 2 (prM) and envelop (E) genes from DENV-1, -3 and -4, resulting in a vaccine product capable of 1 0 3 generating an immune response against all four DENV serotypes [34] . This tetravalent formulation was 1 0 4 also shown to be safe, immunogenic, and capable of providing protective immunity against DENV 1 0 5 challenge in both small animal models and non-human primates [28, 34, 35] . 1 0 6
In this study, we demonstrate that TAK-003 elicits a potent cellular immune response which 1 0 7 persists for at least 120 days post-vaccination in human subjects. The antigen specificity of the cellular 1 0 8 immune response generated by TAK-003 spans the DENV proteome and demonstrates significant cross-1 0 9 reactivity against all four DENV serotypes. Single-cell RNA sequencing analysis of CD8 + T cells 1 1 0 activated in response to TAK-003 exposure revealed a highly polyclonal CD8 + T cell repertoire, which 1 1 1 had significant clonal overlap between DENV-2 non-structural protein (NS)1-and NS3-reactive CD8 + T 1 1 2 cells identified and isolated 120 days post-vaccination. Transcriptional analysis of CD8 + T cells acutely 1 1 3 activated in response to TAK-003 exposure also revealed a highly diverse transcriptional profile, with 1 1 4 NS1-and NS3-reactive memory-precursor CD8 + T cells at day 14 post-immunization displaying a 1 1 5 distinct transcriptional signature dominated by metabolic pathways. Based on these observations, we 1 1 6 identified a panel of metabolic markers which could be used to faithfully identify CD8 + T cells activated 1 1 7 in vitro in response to antigenic stimulation, or activated in vivo in response to TAK-003 administration. 1 1 8
In particular, expression of the transferrin receptor (CD71) -critical for efficient iron uptake -1 1 9 exclusively marks CD8 + T cells with high proliferative and effector/memory potential. Therefore, 1 2 0 analysis of the metabolic profile in vaccine-responsive CD8 + T cells can aid in the identification and 1 2 1 characterization of the most effective and durable vaccine-elicited clonotypes. 1 2 2 1 2 3
RESULTS

2 4
Vaccination with a live-attenuated tetravalent DENV vaccine elicits potent and durable cellular 1 2 5 immunity 1 2 6
T cell activation in response to TAK-003 administration was assessed by flow cytometry in 55 1 2 7 individuals on days 0, 14, 28 and 120 post immunization. Consistent with other live-attenuated vaccine 1 2 8 platforms, TAK-003 administration resulted in significant CD8 + T cell activation on days 14 and 28 1 2 9 post-vaccination ( Figure 1A, Figure 1B, Supplemental Figure 1) . CD8 + T cell activation, as assessed 1 3 0 by CD38/HLA-DR upregulation, peaked on day 28 post-vaccination and returned to baseline levels by 1 3 1 day 120. Moderate CD4 + T cell activation was also observed in response to TAK-003 administration To determine if the extensive T cell activation observed in response to TAK-003 administration 1 3 5 translated to durable cellular immunity, we stimulated PBMCs isolated from study participants on days 1 3 6 0 and 120 of the study with peptide pools corresponding to the NS1, NS3, NS5, and CprM/E proteins of 1 3 7 DENV-1 to -4 and quantified the number of vaccine-reactive, IFN-γ producing cells by ELISPOT assay. 1 3 8
All subjects receiving TAK-003 displayed a significant increase in the number of circulating vaccine-1 3 9 reactive T cells on day 120 relative to baseline (Figure 1E) , with the specificity of this reaction spread 1 4 0 across the DENV proteome ( Figure 1F ). Tetravalent T cell reactivity patterns observed in TAK-003 1 4 1 recipients were detected in both structural (preM/E) and non-structural (NS1-5) regions of the proteome. 1 4 2
Structural region responses could have been generated by any, or all, of the four components of the 1 4 3 vaccine, however, non-structural responses can be interpreted as truly cross-reactive since DENV-2 is 1 4 4 the common non-structural element of the four vaccine components. 1 4 5 TAK-003 exposure generates a highly polyclonal activated CD8 + T cell pool and durable antigen-1 4 6
specific CD8 + memory T cells 1 4 7
To further assess the diversity and persistence of TAK-003-elicited CD8 + T cell immunity, we utilized 1 4 8 single-cell RNA sequencing to track the clonal expansion/contraction of TAK-003-reactive CD8 + T cells 1 4 9 from acute infection time points and memory time points. To identify and isolate TAK-003-reactive 1 5 0 memory CD8 + T cells, we stimulated PBMCs from an individual 120 days post TAK-003 administration 1 5 1 with DENV-2 derived NS1 and NS3 peptide pools which were identified by ELISPOT analysis as being 1 5 2 immunogenic at this time point in this individual (Figure 2A) . Following overnight stimulation with the 1 5 3 DENV-derived peptide pools, DENV-reactive CD8 + T cells were identified by their upregulation of the 1 5 4 early activation markers CD25 and CD69. CD8 + CD25 + CD69 + T cells were isolated by flow cytometric 1 5 5 cell sorting (Figure 2B, Supplemental Figure 2 ) and subjected to single-cell RNA sequencing analysis 1 5 6 using the 10x Genomics Single Cell Analyzer and human TCR V(D)J reagent system. In addition, 1 5 7 vaccine-reactive CD8 + T cells from acute-infection time points (day 14) were identified by expression of 1 5 8 the activation markers CD38 and HLA-DR and isolated by flow sorting (Figure 2C) . A similar number 1 5 9 Figure 7F ), and effector/memory lineage commitment (EOMES) (Figure 7D, Figure 7G ). Expression 3 3 7 of these markers were significantly enriched in CD71 + CD38 + HLA-DR + CD8 + T cells relative to CD71 -3 3 8 CD38 + HLA-DR + CD8 + T cells, or CD38 -HLA-DR -CD8 + T cells. These data demonstrate that the 3 3 9 surface expression of CD71 is a marker of cytolytic cellular functionality and effector/memory potential, 3 4 0 and can further aid in the rapid identification and characterization of vaccine-reactive T cells within the 3 4 1 total "activated" CD8 + T cell pool elicited by vaccine exposure (Figure 7H) . In this study, we demonstrate that the live-attenuated tetravalent DENV vaccine TAK-003 is capable of 3 4 6 eliciting a potent and durable cellular immune response following inoculation. CD8 + T cell activation in 3 4 7 response to TAK-003 administration was observed to peak 28 days post-vaccination, while maximal 3 4 8
CD4 + T cell expansion occurred on day 14. DENV-specific cellular immunity persisted for at least 120 3 4 9 days following immunization as assessed by IFN-γ ELISPOT. The antigenic specificity of the cellular 3 5 0 memory immune response elicited by TAK-003 spanned the entire DENV proteome and exhibited 3 5 1 significant cross-reactivity against all four DENV serotypes. Analysis of the clonotypic and functional 3 5 2 diversity of TAK-003-stimulated CD8 + T cells 14 days after vaccination utilizing scRNAseq revealed a 3 5 3 significant amount of transcriptional heterogeneity within a phenotypically homogenous population. 3 5 4
Isolation and scRNAseq-based analysis demonstrated that the dominant TCR clones within the NS1-3 5 5 and NS3-reactive memory CD8 + T cell populations assessed 120 days post-vaccination can also be 3 5 6 observed within the activated CD38 + HLA-DR + CD8 + T cell compartment 14 days post-vaccination. 3 5 7
scRNAseq-based analysis of these "memory precursor" cells present at day 14 post-vaccination revealed 3 5 8 a unique transcriptional signature, dominated by the gene expression pathways associated with cellular 3 5 9 metabolism and proliferation. 3 6 0
Based on these observations, we were able to develop a panel of markers to assess the metabolic 3 6 1 potential of both CD8 + and CD4 + T cells following in vitro or in vivo activation. These readily 3 6 2 quantifiable metabolic parameters are sensitive and flexible markers of T cell activation and are easily 3 6 3 adapted to standard flow cytometry-based immunoassays. Furthermore, we were able to demonstrate 3 6 4 that surface expression of CD71 (transferrin receptor) marks cells with the highest functional and 3 6 5 proliferative capacity, as assessed by Ki67, Granzyme B, and EOMES expression, providing a robust 3 6 6 marker for identifying the CD8 + T cells shortly after vaccination that are most likely to contribute to a 3 6 7 long-lived memory pool. These data not only provide insight into molecular mechanisms responsible for 3 6 8 regulating memory T cell development, but also suggest possible therapeutic targets for enhancing 3 6 9 vaccine efficacy by selectively priming the metabolism of effector/memory precursor CD8 + T cells 3 7 0 during the critical para-vaccine T cell expansion phase. availability [44] [45] [46] [47] . However, it is becoming increasingly clear that the development of a stable memory 3 7 5
T cell population -as well as T cell effector function and homeostasis in general -is critically 3 7 6 dependent on the availability of a handful of key metabolites and the expression of a corresponding 3 7 7 metabolic cellular program [48] [49] [50] . In particular, the availability of glucose [51, 52] , long-chain fatty 3 7 8 acids [53, 54] , amino acids [55] [56] [57] , and micronutrients such as iron [58, 59] can profoundly impact 3 7 9 CD8 + T cell effector and/or memory potential, in consort with other traditional extrinsic immunological 3 8 0 cues. Depriving T cells of any of these key metabolites either through pharmacological or genetic means 3 8 1 has significant implications for T cell development, effector function, and long-term persistence. 3 8 2
Directly manipulating the metabolism of T cells in vitro or in vivo to influence effector function 3 8 3 or persistence has primarily focused on restricting or enhancing access to the metabolite glucose. Due to 3 8 4 the unique metabolic requirements of nascently activated T cells, which overwhelmingly eschew 3 8 5 conventional mitochondrial oxidative phosphorylation in favor of oxidative glycolysis [48] [49] [50] , glucose 3 8 6 metabolism is a convenient therapeutic target. The proliferation and terminal effector function of both 3 8 7
CD4 + and CD8 + T cells can be significantly enhanced by increasing glucose bioavailability [52, 60] , 3 8 8
whereas restricting glucose metabolism can facilitate the development of long-lived and/or suppressive 3 8 9
T cell lineages [51, 61] . However, the utility of manipulating systemic glucose metabolism for 3 9 0 therapeutic immunoregulatory effect in vivo is questionable. Systemic glucose metabolism is tightly 3 9 1 regulated, and even modest perturbations in systemic glucose availability can have profound negative 3 9 2 consequences for the well-being of patients. However, the selective upregulation of CD71 (transferrin 3 9 3 receptor) on vaccine-reactive CD8 + T cells suggests that manipulating iron availability following 3 9 4 vaccination may selectively enhance the expansion of the most functional vaccine-reactive CD8 + T cells. 3 9 5
Indeed, loss-of-function mutations of the transferrin receptor have been observed and are associated with 3 9 6 severe defects in adaptive immune function, underscoring the importance of transferrin-mediated iron 3 9 7 uptake in maintaining functional immunity [38] . 3 9 8
The findings presented in this study suggest that in the setting of vaccination the preferential 3 9 9 survival of T cells undergoing clonal expansion in vivo is dependent on metabolite availability and the 4 0 0 initiation of a transcriptional program permissive to nutrient uptake. Cell surface expression of the 4 0 1 transporters of these metabolites, such as the transferrin receptor (CD71), during the acute phase 4 0 2 proximal to vaccination, proved to be an effective marker of memory precursor CD8 + T cells. 4 0 3
Cumulatively, these data highlight the utility of high content single-cell transcriptomic analysis coupled 4 0 4 with more traditional cellular immune monitoring in assessing vaccine-elicited T cell immunity. The 4 0 5 ability to accurately and longitudinally track T cell clones from acute infection to stable memory 4 0 6 provides a unique opportunity to identify correlates of T cell-mediated immunity with single-cell 4 0 7 resolution. Future work is required to verify the distinctiveness of the metabolic and transcriptional 4 0 8
programming that determines log-term T cell memory and whether these markers define the protective 4 0 9 capacity of T cell immunity.
The samples used in this study were collected during a Phase 1 trial in US adults of a tetravalent, live-4 1 4 attenuated dengue virus vaccine candidate, TAK-003 (NCT01728792; WRAIR #1987), as well as from 4 1 5 healthy US adult volunteers (WRAIR #1868). TAK-003 samples were provided by Takeda Vaccines. 4 1 6
Whole blood was collected in Cell Preparation Tubes (BD Vacutainer) for isolation of PBMC. Cells 4 1 7
were cryopreserved at approximately 10 7 per mL and stored in vapor-phase liquid nitrogen until use. Cryopreserved PBMC were thawed and placed in RPMI 1640 medium supplemented with 10% heat-4 2 5 inactivated normal human serum (100-318, Gemini Bio-Products), L-glutamine, penicillin, and 4 2 6 streptomycin. After an overnight rest at 37°C, the PBMC were washed, resuspended in serum-free 4 2 7 medium (SFM; X-VIVO 15, Lonza), and 1-2x10 5 cells were plated per well of a 96-well Millipore 4 2 8 MAIPSWU plate coated with anti-IFNγ antibody according to the manufacturer's instructions (3420-4 2 9
2HW-Plus, Mabtech Inc.). Peptide pools were added to the cells at a final concentration of 4 3 0 1μg/mL/peptide prior to incubation at 37°C overnight. Controls included SFM plus 0.5% DMSO 4 3 1 (negative) and anti-CD3 (positive). The ELISpot plates were developed using TMB substrate and read 4 3 2 using a CTL-ImmunoSpot® S6 Ultimate-V Analyzer (Cellular Technology Limited). 4 3 3 4 3 4
Peptides 4 3 5
Overlapping peptide pools corresponding to the full-length envelope (E), non-structural 1 (NS1), NS2, 4 3 6 NS3, NS4, and NS4 proteins for DENV-1-4 were obtained through the NIH Biodefense and Emerging 4 3 7
Infections Research Resources Repository, NIAID, NIH (Supplemental Table 2 ). Additional 4 3 8 overlapping peptide pools covering the capsid (C) and precursor membrane (prM) proteins of DENV-1-4 3 9 4, pp65 protein from hCMV, nucleocapsid protein from influenza H3N2, hexon protein from adenovirus 4 4 0 serotype 3, and Large Envelope protein from HBV were purchased from JPT Peptide Technologies 4 4 1 Table 2 ). Peptide pool stocks were reconstituted in DMSO at a concentration of 4 4 2 200μg/mL/peptide and stored at -80°C. Polyclonal T cell activation was performed by stimulating healthy donor PBMCs at a concentration of 4 5 5 5x10 6 cells/mL with 0.1 μg/mL αCD3 (Clone OKT3, Biolegend 317315) and 1 μg/mL αCD28 (Clone 4 5 6 CD28.2, BD 555725) in complete cell culture media consisting of RPMI 1640 supplemented with 10% 4 5 7
(Supplemental
heat-inactivated fetal bovine serum (Sigma), 2 mM L-glutamine (Lonza/BioWhittaker), and 100 U/ml 4 5 8 penicillin/streptomycin (Lonza/BioWhittaker). For antigen-specific T cell simulation, healthy donor 4 5 9
PBMCs were resuspended at a concentration of 5x10 6 cells/mL in complete cell culture media and 4 6 0 stimulated with the indicated peptide pool at a final concentration of 1 μg/mL. Cryopreserved PBMC samples were thawed and resuspended in complete cell culture media at a 4 7 2 concentration of 5x10 6 cell/mL and rested for 30 min at 37 o C prior to metabolic analysis. For 4 7 3 assessment of glucose uptake, cells were subsequently washed 2X with glucose-free RPMI 4 7 4 (ThermoFisher, N13195), resuspended at a concentration of 5x10 6 cell/mL in glucose-free RPMI, and 4 7 5 rested for an additional 10 minutes at 37 o C. 2-NBDG (ThermoFisher, D3821) was added to a final 4 7 6 concentration of 100μM, and cells were incubated for 30 minutes at 37 o C. Cells were washed 2X with 4 7 7 PBS + 5% FBS, then surface stained for flow cytometry analysis as described above. For assessment of 4 7 8 fatty-acid uptake, BODIPY FL-C 16 was added to cells in complete cell culture media at a final 4 7 9 concentration of 1μM. Cells were incubated for 30 minutes at 37 o C, then washed 2X with PBS + 5% 4 8 0 FBS and surfaced stained for flow cytometry analysis as described above. Flow-sorted CD8 + T cell suspensions at a density of 50-500 cells/μL in PBS plus 0.5% FBS were 4 8 4 prepared for single-cell RNA sequencing using the Chromium Single Cell 5' Reagent version 2 kit and 4 8 5
Chromium Single Cell Controller (10x Genomics, CA) as previously described with some modification 4 8 6
[42]. In short, 500 -2,000 cells per reaction were loaded for gel bead-in-emulsion (GEM) generation High Output Kit v2 (150 cycles) to a read depth of ~30,000 reads/cell. Sequencing parameters were set 4 9 6
for Read1 (26 cycles), Index1 (8 cycles), and Read2 (98 cycles). scRNAseq TCR V(D)J enriched library 4 9 7 sequencing was performed on an Illumina MiSeq platform with a v3 Reagent Kit (600 cycles) to a read 4 9 8 depth of ~10,000 reads/cell. Sequencing cycles were set at 150 for Read1, 8 for Index1 ), and 150 for 4 9 9
Read2. Prior to sequencing, library quality and concentration were assessed using an Agilent 4200 5 0 0
TapeStation with High Sensitivity D5000 ScreenTape Assay and Qubit Fluorometer (Thermo Fisher 5 0 1 Scientific) with dsDNA BR assay kit according to the manufacturer's recommendation. 5 0 2 5 0 3 10x Genomics 5' gene-expression data analysis 5 0 4 5' gene expression analysis from sorted CD8 + T cells was performed using the 10x Genomics Cell 5 0 5
Ranger pipeline as previously described [42] . In short, sample demultiplexing and analysis was 5 0 6 performed using the Cell Ranger software package (10x Genomics, CA, v2.1.0) according to the 5 0 7 manufacturer's recommendations, with the default settings, and mkfastq/count commands, respectively. 5 0 8
Transcript alignment was performed against a human reference library generated using the Cell Ranger 5 0 9 mkref command and the Ensembl GRCh38 v87 top-level genome FASTA and the corresponding 5 1 0
Ensembl v87 gene GTF. Data visualization and differential gene expression analysis were performed 5 1 1 using the Loupe Cell Browser (10x Genomics, CA, v2.0.0). t-SNE plot visualization of gene expression 5 1 2 data was based on the cellular coordinates calculated by the Cell Ranger count command. 5 1 3 5 1 4 TCR sequence analysis 5 1 5
Sorted CD8 + T cell TCR clonotype identification, alignment, and annotation was performed using the 5 1 6
10x Genomics Cell Ranger pipeline. Sample demultiplexing and clonotype alignment was performed 5 1 7
using the Cell Ranger software package (10x Genomics, CA, v2.1.0) according to the manufacturer's 5 1 8 recommendations, with the default settings, and mkfastq/vdj commands, respectively. TCR clonotype 5 1 9 alignment was performed against a filtered human V(D)J reference library generated using the Cell 5 2 0
Ranger mkvdjref command and the Ensembl GRCh38 v87 top-level genome FASTA and the 5 2 1 corresponding Ensembl v87 gene GTF. TCR clonotype visualization, diversity assessment, and analysis 5 2 2 Z  h  e  n  g  ,  G  .  X  .  ,  e  t  a  l  .  ,  M  a  s  s  i  v  e  l  y  p  a  r  a  l  l  e  l  d  i  g  i  t  a  l  t  r  a  n  s  c  r  i  p  t  i  o  n  a  l  p  r  o  f  i  l  i  n  g  o  f  s  i  n  g  l  e  c  e  l  l  s  .  N  a  t  6  3  0  C  o  m  m  u  n  ,  2  0  1  7  .  8  :  p  .  1  4  0  4  9  .  6  3  1  4  3  .  B  l  a  i  r  ,  D  .  A  .  ,  e  t  a  l  .  ,  D  u  r  a  t  i  o  n  o  f  a  n  t  i  g  e  n  a  v  a  i  l  a  b  i  l  i  t  y  i  n  f  l  u  e  n  c  e  s  t  h  e  e  x  p  a  n  s  i  o  n  a  n  d  m  e  m  o  r  y  6  3  2  d  i  f  f  e  r  e  n  t  i  a  t  i  o  n  o  f  T  c  e  l  l  s  .  J  I  m  m  u  n  o  l  ,  2  0  1  1  .  1  8  7  (  5  )  :  p  .  2  3  1  0  -2  1  .  6  3  3 CAVMDSNYQLIW  TRAV1-2  TRAJ33  CASSEGAKNIQYF  TRBV6-4  --TRBJ2-4  0.009756  CASMDSNYQLIW  TRAV1-2  TRAJ33  CATSDLVQGDTGELFF  TRBV24-1  TRBD1  TRBJ2-2  0.008362 CAMNTDAGGTSYGKLTF TRAV12-3  TRAJ52  CAIRQGNTEAFF  TRBV10-3  TRBD1  TRBJ1-1  0.006969  CAVMDSNYQLIW  TRAV1-2  TRAJ33  CSARQGEYEQYF  TRBV20-1  TRBD1  TRBJ2-7  0.006272  CGRRGPPTDKLIF  TRAV13-2  TRAJ34  CASSQGPTVGQPQHF  TRBV4-1  TRBD1  TRBJ1-5  0.005575  CAVRDDRGEGTYKYIF  TRAV3  TRAJ40  CASSLSQGYQPQHF  TRBV7-6  TRBD1  TRBJ1-5  0.004878  CAVMDSNYQLIW  TRAV1-2  TRAJ33  CSARGGLEVDTQYF  TRBV20-1  TRBD1  TRBJ2- CAVQAQGYSTLTF  TRAV20  TRAJ11  CASSELDNEQFF  TRBV2  --TRBJ2-1  0.07908163 CAVGSPLYSGGGADGLTF  TRAV8-3  TRAJ45  CASSLAGGYEQYF  TRBV5-6  TRBD2  TRBJ2-7  0.05102041  CAVQAGGYSTLTF  TRAV20  TRAJ11  CASAEADNEQFF  TRBV13  TRBD2  TRBJ2-1  0.04336735  CAVNGGVGNQFYF  TRAV12-2  TRAJ49  CSTGTPGQPLSYEQYF  TRBV20-1  TRBD1  TRBJ2-7  0.03826531 CAASWYSGGGADGLTF TRAV29DV5 TRAJ45  CASSQSDRSTYNEQFF  TRBV4-3  --TRBJ2-1  0.02806122  CAGTGGADGLTF  TRAV12-2  TRAJ45  CASNPGSPEAFF  TRBV2  TRBD2  TRBJ1-1  0.02806122  CAADGGSQGNLIF  TRAV21  TRAJ42  CASSEWIGTEAFF  TRBV6-1  --TRBJ1-1  0.0255102  CAVLNSGYSTLTF  TRAV21  TRAJ11  CATSGVGDRGFDNEQFF TRBV24-1  TRBD1  TRBJ2-1  0.0255102  CALDIMDSSYKLIF  TRAV6  TRAJ12  CATSDLGLPEETQYF  TRBV24-1  TRBD2  TRBJ2-5  0.01785714  CAVDNNNARLMF  TRAV39  TRAJ31  CASSPRFGDTYEQYF  TRBV11-3  TRBD1 TRBJ2-7 
